| Clinical data | |
|---|---|
| Other names | U-7265; 5α-Dihydrofluoxymesterone; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-dihydrotestosterone; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-DHT; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-androstan-17β-ol-3-one |
| Routes of administration | By mouth |
| Drug class | Androgen;Anabolic steroid |
| Identifiers | |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H31FO3 |
| Molar mass | 338.463 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dihydrofluoxymesterone (developmental code nameU-7265) is anandrogen andanabolic steroid (AAS) which was never marketed.[1][2][3] It was assessed in the treatment ofbreast cancer in women in at least oneclinical study in the 1970s and showed effectiveness similar to that of other AAS.[1][2] The drug is the5α-reducedanalogue andmetabolite offluoxymesterone.[1][2][3]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |